See Asa at Microbiome & Probiotic R&D & Business Collaboration Forum - La Jolla, California 10/13/2025
April 27, 2022 By: Asa Waldstein

Product Tags & Metatags Attract FDA Attention

Takeaway -

Everything used to market products must be compliant

Website product tags and metatags continue to attract FDA attention in warning letters.

This year three warning letters mention product tags or “category” tags. These tags help people find products when they search for things on Google or a website, and they are considered marketing in the eyes of the FDA and FTC.

Although these tags are an “extension of the label,” they are not likely to attract a warning letter on their own. However, they signal intended use, which can lead authorities to a commercial website to keep digging for claims once there.

Here are some examples involving product tags and metatags with disease claims. It’s worth noting that additional high-risk website and social media claims are also present in each warning letter. This is an important reminder that compliance is not done in a vacuum, and all online content must be free of high-risk claims to avoid warning letters.

From Warning Letter: “From the product webpage at …. Tags: anxiety, . . . memory, mental performance, natural depression remedy”

Read this warning letter here.

From Warning Letter:Tags: anti-viral, COVID, COVID-19, Cure

Read this warning letter here.

From Warning Letter: “The above noted website claims are supplemented by metatags used to bring consumers to your website ….. through Internet searches. The metatags are: • “Take Altitude RX for altitude sickness prevention…”

Read this warning letter here.

Here is my “All Marketing is Labeling” video.

Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading.

Written by

Asa Waldstein
Asa Waldstein
Asa Waldstein is a 24-year veteran of the dietary supplement industry, with experience spanning manufacturing, marketing, and regulatory compliance. He is the principal of Apex Compliance, a software company dedicated to streamlining regulatory marketing compliance for the dietary supplement and natural products sectors. Asa also leads Supplement Advisory Group, a boutique consultancy focused on marketing risk analysis, labeling, and practical compliance strategies for websites and social media. Asa has helped oversee three FDA GMP inspections with no 483s and was honored with the 2023 AHPA Herbal Hero Award and the 2024 What's Up Supps Policy and Change Agent Award. He currently serves as Chair of the American Herbal Products Association’s (AHPA) Cannabis Committee, helping shape policy and industry best practices